Trials / Completed
CompletedNCT04848571
Effects of Chinese Medicine on Early Pregnant Women
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (actual)
- Sponsor
- Shanghai Meiji Health Science and Technology Co., Ltd. · Industry
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
From April 2021 to December 2021, 45 pregnant women who received intro fertilization-embyro transfer (IVF-ET) were recuited. According to their own wishes, 28 of them took Chinese medicine from the 2nd week after embryo transfer (intervention group), while the remaining 17 did not intake Chinese medicine (control group). Blood and feces samples were collected in the early morning of the 4th week after embryo transfer to detect 16S DNA sequences in feces, plasma metabolites, and whole blood transcriptomics.
Detailed description
Investigators planned to performed a observational clinical trial to determine the effects of the Chinese medicine (Gushen Antai recipe) including mainly Rehmannia glutinosa used in pregnant women for fetal protection. Two groupswere recruited, Chinese medicine intervention group and control group without Chinese medicine. In the 4th week after embryo transfer, blood and fetal were sampled for metabolic and intestinal microbiota analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Fetal Protection Pill | A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2021-11-01
- Completion
- 2021-11-02
- First posted
- 2021-04-19
- Last updated
- 2025-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04848571. Inclusion in this directory is not an endorsement.